| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CTGF |
| Clinical data | |
| Other names | FG-3019 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6492H10018N1718O2086S48 |
| Molar mass | 147050.38 g·mol |
Pamrevlumab (INN; development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.
This drug was developed by FibroGen, Inc.
References
- World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- Sgalla G, Franciosa C, Simonetti J, Richeldi L (August 2020). "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis". Expert Opinion on Investigational Drugs. 29 (8): 771–777. doi:10.1080/13543784.2020.1773790. PMID 32447983. S2CID 218873298.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |